Novartis has triggered a $50 million milestone payment to Monte Rosa Therapeutics following the dosing of the first patient in their VAV1‑targeted drug partnership.
Further verified details were not immediately available.
Novartis triggers $50M milestone payment to Monte Rosa after first patient dose
Novartis has made a $50 million milestone payment to Monte Rosa Therapeutics after the first patient was dosed in their VAV1‑targeted drug collaboration.
PA
Priya Anand · Equities & Earnings Desk · 13 Sept 2026 · 13:23 · 1 min read
This article was produced with AI assistance and edited by a Finance Review Daily journalist.
ADVERTISEMENT
PA
Written by
Priya Anand
Equities & Earnings Desk
Priya covers listed equities and corporate earnings, reading quarterly results and guidance for what they signal about sector health and forward valuations.
More from Priya Anand →
